Clinical Trials Browser

Uveal Melanoma, Bone Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Eye Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Osteosarcoma, Skin Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Breast Neoplasms, Male, Muscle Neoplasms, Genetic Diseases, Inborn, Histiocytoma, Malignant Fibrous

Clinical Trials

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

TEIPP

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Vaccine Therapy in Treating Patients With Metastatic Cancer

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Mel-65

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

MEL58

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors

Immunotherapy of Melanoma Patients

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer